ARS Pharma cuts 2026 cash operating expense outlook to $248 million excluding COGS

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc.

SPRY

0.00
  • ARS Pharmaceuticals cut its 2026 cash-based operating expense outlook, excluding COGS, to about USD 248 million on lower second-half spending.
  • It reaffirmed expectations that the neffy base business supports a path to cash-flow breakeven in 2027.
  • Florida Medicaid adds neffy to its unrestricted formulary effective July 1, 2026; no new commercial formulary additions were issued for the July 1 cycle.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.